The German biotech has signed a $1 billion-plus deal with China’s Biotheus, which includes $55 million upfront, to claim rights to a bispecific antibody for solid tumours in all markets outside Greater China.
The drug – codenamed PM8002 – consists of an antibody that targets both PD-L1, a well-established cancer immunotherapy target, and VEGF-A, a protein involved in the growth and spread of solid tumours.
